ElizabethR.PlimackMDMS
Oncology • Philadelphia, PAGenitourinary Oncology
Chief, Division of Genitourinary Medical Oncology. Director, Genitourinary Clinical Research. Associate Professor, Department of Hematology/Oncology.
Dr. Plimack is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
Fox Chase Cancer Center
Philadelphia, PA 19111Phone+1 215-728-6900Fax+1 215-728-3639
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
NYU Grossman School of MedicineResidency, Internal Medicine, 2002 - 2005- New York University School of MedicineClass of 2002
Certifications & Licensure
PA State Medical License 2008 - 2024
TX State Medical License 2005 - 2008- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
- Dose Dense MVAC for Muscle Invasive Bladder Cancer Start of enrollment: 2009 Dec 07
- Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2010 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 39 citationsCoexisting Hybrid Malignancy in a Solitary Sporadic Solid Benign Renal Mass: Implications for Treating Patients Following Renal BiopsySerge Ginzburg, Robert G. Uzzo, Tahseen Al-Saleem, Essel Dulaimi, John Walton
The Journal of Urology. 2014-02-01 - 90 citationsERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder CancerQiang Li, Alexis W. Damish, Zoë Frazier, David Liu, Elizaveta Reznichenko
Clinical Cancer Research. 2019-02-01 - 189 citationsClinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.David Liu, Elizabeth R. Plimack, Jean H. Hoffman-Censits, Levi A. Garraway, Joaquim Bellmunt
JAMA Oncology. 2016-08-01
Journal Articles
- Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based ImmunotherapyJonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine
Press Mentions
ASCO GU 2023: Update on Bladder-Sparing Treatment Trial: RETAIN BLADDERFebruary 15th, 2023- Neoadjuvant Chemotherapy Shows “Clear Benefit” in Upper Tract Urothelial CarcinomaJanuary 26th, 2023
- Practice-Changing Presentations in Renal Cell Carcinoma: Insights from ASCO® 2021July 5th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
